ClinicalTrials.govcontrolled
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
ClinicalTrials.gov study NCT02089685. IPD Sharing: YES. Countries: 0. Publications: 3.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 12
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 8